Elexacaftor–Tezacaftor–Ivacaftor Improves Sinonasal Outcomes in Young Children With Cystic Fibrosis
ETI improves sinonasal symptoms and endoscopy findings in children 6-11 years of age. Olfaction did not improve with ETI treatment in this age group, suggesting that olfactory dysfunction associated with CF is established early in life. This younger cohort of pediatric patients presented with abundant Staphylococcus aureus and only very rare Pseudomonas aeruginosa at baseline or after treatment.
Authors
- Anna C. Zemke (ORCID: https://orcid.org/0000-0002-7722-6708)
- Amanda L. Stapleton (ORCID: https://orcid.org/0000-0001-8926-2733)
- Barton F. Branstetter (ORCID: https://orcid.org/0000-0002-8502-6909)
- Amber D. Shaffer (ORCID: https://orcid.org/0000-0001-5783-9198)
- Jennifer L. Goralski (ORCID: https://orcid.org/0000-0002-6785-5076)
- Adam J. Kimple (ORCID: https://orcid.org/0000-0003-1670-8401)
- Daniel M. Beswick (ORCID: https://orcid.org/0000-0001-8612-5442)
- Ashutosh Gupta (ORCID: https://orcid.org/0000-0003-2785-5837)
- Mehdi syed Nouraie (ORCID: https://orcid.org/0000-0001-7465-0581)
- Brent A. Senior (ORCID: https://orcid.org/0000-0002-1503-3150)
- Douglas Li
Institutions
- University of North Carolina at Chapel Hill (US)
- University of California, Los Angeles (US)
- University of Pittsburgh (US)
Publication Details
- Journal
- International Forum of Allergy & Rhinology
- Published
- 2025-03-02
- DOI
- https://doi.org/10.1002/alr.23555
- Citations
- 4
- Primary Topic
- Cystic Fibrosis Research Advances
- Type
- article
- Field-Weighted Citation Impact
- 6.07
Funders
- Cystic Fibrosis Foundation
- University of Pittsburgh